holmes schreef op 12 maart 2023 14:35:
Standard FDA Calendar
This calendar tracks upcoming PDUFA drug approval dates and FDA advisory committee meetings.
www.fdatracker.com/fda-calendar/Hier staat: Acadia Pharmaceuticals, 12 maart 2023
Gisteren (11 maart 2023) was er een persbericht van Acadia Pharmaceuticals:
Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older
Sat, March 11, 2023 at 3:45 AM GMT+1
-- First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S.1
-- Company expects DAYBUE to be available by the end of April, 2023
-- Rare Pediatric Disease Priority Review Voucher granted in connection with approval
-- Conference call and webcast to be held March 13, 2023 at 8:30 a.m. Eastern Time
finance.yahoo.com/news/acadia-pharmac...